Inogen (INGN) 10-Q 5 May 23 2023 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2023	Apr. 28, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Trading Symbol	INGN
Entity Registrant Name	INOGEN, INC.
Entity Central Index Key	0001294133
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Current Reporting Status	Yes
Entity Common Stock, Shares Outstanding		23,121,377
Document Quarterly Report	true
Document Transition Report	false
Title of 12(b) Security	Common Stock, $0.001 par value
Security Exchange Name	NASDAQ
Entity File Number	001-36309
Entity Tax Identification Number	33-0989359
Entity Address, Address Line One	301 Coromar Drive
Entity Address, City or Town	Goleta
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	93117
City Area Code	(805)
Local Phone Number	562-0500
Entity Interactive Data Current	Yes
Entity Incorporation, State or Country Code	DE

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 164,137	$ 187,014
Marketable securities	10,428
Accounts receivable, net	53,885	62,725
Inventories, net	38,822	34,093
Income tax receivable	1,859	1,626
Prepaid expenses and other current assets	14,016	19,187
Total current assets	283,147	304,645
Property and equipment, net	45,942	43,269
Goodwill	32,887	32,852
Operating lease right-of-use asset	21,108	21,653
Other assets	2,590	2,622
Total assets	385,674	405,041
Current liabilities
Accounts payable and accrued expenses	32,183	33,974
Accrued payroll	10,757	11,190
Warranty reserve - current	8,075	7,790
Operating lease liability - current	3,570	3,515
Deferred revenue - current	8,794	8,880
Total current liabilities	63,379	65,349
Long-term liabilities
Warranty reserve - noncurrent	12,018	12,123
Operating lease liability - noncurrent	19,179	19,764
Deferred revenue - noncurrent	9,801	10,399
Total liabilities	104,377	107,635
Commitments and contingencies (Note 9)
Stockholders' equity
Common stock, $0.001 par value per share; 200,000,000 authorized; 23,120,786 and 22,941,643 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively	23	23
Additional paid-in capital	316,127	312,126
Accumulated deficit	(34,849)	(14,500)
Accumulated other comprehensive loss	(4)	(243)
Total stockholders' equity	281,297	297,406
Total liabilities and stockholders' equity	$ 385,674	$ 405,041

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	23,120,786	22,941,643
Common stock, shares outstanding	23,120,786	22,941,643

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue
Sales revenue	$ 55,887	$ 67,402
Rental revenue	16,275	12,983
Total revenue	72,162	80,385
Cost of revenue
Cost of sales revenue	33,964	39,500
Cost of rental revenue, including depreciation of $3,078 and $2,638, respectively	7,465	5,879
Total cost of revenue	41,429	45,379
Gross profit
Gross profit-sales revenue	21,923	27,902
Gross profit-rental revenue	8,810	7,104
Total gross profit	30,733	35,006
Operating expense
Research and development	5,344	5,364
Sales and marketing	28,441	28,039
General and administrative	18,863	15,189
Total operating expense	52,648	48,592
Loss from operations	(21,915)	(13,586)
Other income (expense)
Interest income	1,525	29
Other income (expense)	237	(433)
Total other income (expense), net	1,762	(404)
Loss before provision for income taxes	(20,153)	(13,990)
Provision for income taxes	196	224
Net loss	(20,349)	(14,214)
Other comprehensive income (loss), net of tax
Change in foreign currency translation adjustment	170	(203)
Change in net unrealized gains (losses) on foreign currency hedging		(528)
Less: reclassification adjustment for net (gains) losses included in net income		454
Total net change in unrealized gains (losses) on foreign currency hedging		(74)
Change in net unrealized gains (losses) on marketable securities	69	(8)
Total other comprehensive income (loss), net of tax	239	(285)
Comprehensive loss	$ (20,110)	$ (14,499)
Basic net loss per share attributable to common stockholders (Note 6)	$ (0.88)	$ (0.62)
Diluted net loss per share attributable to common stockholders (Note 6)	$ (0.88)	$ (0.62)
Weighted average number of shares used in calculating net loss per share attributable to common stockholders:
Basic common shares	23,009,617	22,754,421
Diluted common shares	23,009,617	22,754,421

Consolidated Statements of Co_2

Consolidated Statements of Comprehensive Loss (Parenthetical) (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Depreciation	$ 3,078	$ 2,638

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Retained earnings	Accumulated other comprehensive income
Beginning Balance at Dec. 31, 2021	$ 370,227	$ 23	$ 299,463	$ 69,272	$ 1,469
Beginning Balance, shares at Dec. 31, 2021		22,731,586
Stock-based compensation	2,665		2,665
Employee stock purchases	915		915
Employee stock purchases, shares		30,558
Vesting of restricted stock units	(958)		(958)
Vesting of restricted stock units, shares		73,495
Shares withheld related to net restricted stock settlement	(94)		(94)
Shares withheld related to net restricted stock settlement, shares		(2,666)
Stock options exercised	29		29
Stock options exercised, shares		3,499
Net loss	(14,214)			(14,214)
Other comprehensive income (loss)	(285)				(285)
Ending Balance at Mar. 31, 2022	358,285	$ 23	302,020	55,058	1,184
Ending Balance, shares at Mar. 31, 2022		22,836,472
Beginning Balance at Dec. 31, 2022	297,406	$ 23	312,126	(14,500)	(243)
Beginning Balance, shares at Dec. 31, 2022		22,941,643
Stock-based compensation	3,442		3,442
Employee stock purchases	630		630
Employee stock purchases, shares		47,676
Vesting of restricted stock units	(454)		(454)
Vesting of restricted stock units, shares		77,530
Shares withheld related to net restricted stock settlement	(1)		(1)
Shares withheld related to net restricted stock settlement, shares		(495)
Stock options exercised	$ 384		384
Stock options exercised, shares	54,432	54,432
Net loss	$ (20,349)			(20,349)
Other comprehensive income (loss)	239				239
Ending Balance at Mar. 31, 2023	$ 281,297	$ 23	$ 316,127	$ (34,849)	$ (4)
Ending Balance, shares at Mar. 31, 2023		23,120,786

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities
Net loss	$ (20,349)	$ (14,214)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	4,086	5,760
Loss on rental units and other assets	1,099	706
Gain on sale of former rental assets	(21)	(52)
Provision for sales revenue returns and doubtful accounts	2,258	2,953
Provision for inventory losses	603	934
Stock-based compensation expense	3,442	2,665
Change in fair value of earnout liability		630
Changes in operating assets and liabilities:
Accounts receivable	6,726	(12,802)
Inventories	(6,362)	(2,515)
Income tax receivable	(233)	(92)
Prepaid expenses and other current assets	5,173	764
Operating lease right-of-use asset	550	832
Other noncurrent assets	47	66
Accounts payable and accrued expenses	(1,845)	6,539
Accrued payroll	(436)	(8,465)
Warranty reserve	180	(633)
Deferred revenue	(684)	(231)
Income tax payable		(79)
Operating lease liability	(535)	(864)
Net cash used in operating activities	(6,301)	(18,098)
Cash flows from investing activities
Purchases of available-for-sale securities	(10,359)
Investment in property and equipment	(1,076)	(1,366)
Production and purchase of rental equipment	(5,733)	(2,777)
Proceeds from sale of former assets	58	91
Net cash used in investing activities	(17,110)	(4,052)
Cash flows from financing activities
Proceeds from stock options exercised	384	29
Proceeds from employee stock purchases	630	915
Payment of employment taxes related to release of restricted stock	(455)	(1,052)
Net cash provided by (used in) financing activities	559	(108)
Effect of exchange rates on cash	(25)	133
Net decrease in cash and cash equivalents	(22,877)	(22,125)
Cash and cash equivalents, beginning of period	187,014	235,524
Cash and cash equivalents, end of period	164,137	213,399
Supplemental disclosures of cash flow information
Cash paid during the period for income taxes, net of refunds received	418	372
Supplemental disclosure of non-cash transactions
Property and equipment in accounts payable and accrued liabilities	$ 65	$ 91

Business Overview

Business Overview	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Overview	1. Business overview Inogen, Inc. (Company or Inogen) was incorporated in Delaware on November 27, 2001. The Company is a medical technology company that primarily develops, manufactures and markets innovative portable oxygen concentrators (POCs) used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Traditionally, these patients have relied on stationary oxygen concentrator systems for use in the home and oxygen tanks or cylinders for mobile use, which the Company calls the delivery model. The tanks and cylinders must be delivered regularly and have a finite amount of oxygen, which requires patients to plan activities outside of their homes around delivery schedules and a finite oxygen supply. Additionally, patients must attach long, cumbersome tubing to their stationary concentrators simply to enable mobility within their homes. The Company’s proprietary Inogen One ® systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a single battery and can be plugged into an outlet when at home, in a car, or in a public place with outlets available. The Company’s Inogen One systems reduce the patient’s reliance on stationary concentrators and scheduled deliveries of tanks with a finite supply of oxygen, thereby improving patient quality of life and fostering mobility. The Company incorporated Inogen Europe Holding B.V., a Dutch limited liability company, on April 13, 2017 . On May 4, 2017, Inogen Europe Holding B.V. acquired all issued and outstanding capital stock of MedSupport Systems B.V. (MedSupport) and began operating under the name Inogen Europe B.V. The Company merged Inogen Europe Holding B.V. and Inogen Europe B.V. on December 28, 2018. Inogen Europe B.V. is the remaining legal entity. Inogen completed the acquisition of New Aera, Inc. (New Aera) on August 9, 2019.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	2. Basis of presentation and summary of significant accounting policies The consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). The results of operations for the three months ended March 31, 2023 shown in this report are not necessarily indicative of results to be expected for the full year ending December 31, 2023. In the opinion of the Company’s management, the information contained herein reflects all adjustments, consisting of only normal recurring adjustments, necessary for a fair presentation of the Company’s results of operations, financial position, cash flows and stockholders’ equity. Certain footnote disclosures normally included in annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to Securities and Exchange Commission (SEC) rules and regulations relating to interim financial statements. The accompanying consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K filed with the SEC on February 24, 2023. Except as further described below, there have been no significant changes in the Company’s accounting policies from those disclosed in its Annual Report on Form 10-K filed with the SEC on February 24, 2023. Basis of consolidation The consolidated financial statements include the accounts of Inogen, Inc. and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated. Use of estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases these estimates and assumptions upon historical experience, existing and known circumstances, authoritative accounting pronouncements and other factors that management believes to be reasonable. Significant areas requiring the use of management estimates relate to revenue recognition, warranty reserves and expense, determining the stand-alone selling price (SSP) and service period of performance obligations, rental asset valuations and write-downs, accounts receivable allowances for bad debts, returns and adjustments, impairment of goodwill, impairment of long-lived assets, stock-based compensation expense, and income taxes. Actual results could differ from these estimates. Restructuring charges Restructuring costs include workforce reductions, termination benefits, centralizing manufacturing activities, outsourcing, contract termination, and equipment relocation. Key assumptions used in calculating the restructuring costs include the terms of, and payments under, agreements to terminate certain contractual obligations and the timing of reductions in workforce .

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	3. Fair value measurements Cash, cash equivalents and marketable securities The following table summarizes fair value measurements by level for the assets measured at fair value on a recurring basis for cash, cash equivalents and marketable securities: As of March 31, 2023 Gross Cash Adjusted unrealized and cash Marketable cost gains Fair value equivalents securities Cash $ 23,864 $ — $ 23,864 $ 23,864 $ — Level 1: Money market accounts 99,048 — 99,048 99,048 — Level 2: Corporate bonds 5,985 — 5,985 5,985 — U.S. Treasury securities 25,253 95 25,348 14,920 10,428 Institutional Insured Liquidity Deposit Savings 20,320 — 20,320 20,320 — Total $ 174,470 $ 95 $ 174,565 $ 164,137 $ 10,428 As of December 31, 2022 Gross Cash Adjusted unrealized and cash cost gains Fair value equivalents Cash $ 27,970 $ — $ 27,970 $ 27,970 Level 1: Money market accounts 113,534 — 113,534 113,534 Level 2: Corporate bonds 6,474 — 6,474 6,474 U.S. Treasury securities 18,913 26 18,939 18,939 Institutional Insured Liquidity Deposit Savings 20,097 — 20,097 20,097 Total $ 186,988 $ 26 $ 187,014 $ 187,014 Derivative instruments and hedging activities The Company records the assets or liabilities associated with derivative instruments and hedging activities at fair value based on Level 2 inputs in other current assets or other current liabilities, respectively, in the consolidated balance sheet. The Company had a related payable of $ 203 and $ 422 as of March 31, 2023 and December 31, 2022, respectively. Accumulated other comprehensive income (loss) The components of accumulated other comprehensive income (loss) were as follows: Foreign Unrealized Accumulated currency gains other translation on marketable comprehensive adjustments securities income (loss) Balance as of December 31, 2022 $ ( 269 ) $ 26 $ ( 243 ) Other comprehensive income 170 69 239 Balance as of March 31, 2023 $ ( 99 ) $ 95 $ ( 4 ) Comprehensive income (loss) is the total net earnings and all other non-owner changes in equity. Except for foreign currency translation adjustments and unrealized gains and losses on marketable securities, the Company does not have any transactions or other economic events that qualify as other comprehensive income (loss).

Balance Sheet Components

Balance Sheet Components	3 Months Ended
	Mar. 31, 2023
Balance Sheet Related Disclosures [Abstract]
Balance Sheet Components	4. Balance sheet components Cash, cash equivalents and marketable securities Cash, cash equivalents and marketable securities consist of the following: March 31, December 31, Cash and cash equivalents 2023 2022 Cash $ 23,864 $ 27,970 Money market accounts 99,048 113,534 Corporate bonds 5,985 6,474 U.S. Treasury securities 14,920 18,939 Institutional Insured Liquidity Deposit Savings 20,320 20,097 Total cash and cash equivalents $ 164,137 $ 187,014 Marketable securities U.S. Treasury securities 10,428 — Total marketable securities $ 10,428 $ — Accounts receivable and allowance for bad debts, returns, and adjustments Net accounts receivable (gross accounts receivable, net of allowances) balance concentrations by major category as of March 31, 2023 and December 31, 2022 were as follows: March 31, December 31, Net accounts receivable 2023 2022 Rental (1) $ 7,392 $ 5,246 Business-to-business and other receivables (2) 46,493 57,479 Total net accounts receivable $ 53,885 $ 62,725 (1) Rental includes Medicare, Medicaid/other government, private insurance and patient pay. (2) Business-to-business receivables included extended terms for two customers: 1) One customer had accounts receivable balances of $ 7,734 and $ 9,861 as of March 31, 2023 and December 31, 2022 , respectively. The customer received extended payment terms through a direct financing plan offered. The Company also has a credit insurance policy in place, which allocated up to $ 12,000 in coverage as of March 31, 2023 and December 31, 2022 , for this customer with a $ 400 deductible and 10 % retention; and 2) One customer had an accounts receivable balance of $ 18,757 and $ 22,641 as of March 31, 2023 and December 31, 2022. The following table sets forth the accounts receivable allowances as of March 31, 2023 and December 31, 2022: March 31, December 31, Allowances - accounts receivable 2023 2022 Doubtful accounts $ 156 $ 77 Sales returns 699 483 Total allowances - accounts receivable $ 855 $ 560 Concentration of customers and vendors The Company primarily sells its products to traditional home medical equipment providers, distributors, and resellers in the United States and in foreign countries on a credit basis. The Company also sells its products direct-to-consumers primarily on a prepayment basis. Two customers each represented more than 10% of the Company’s net accounts receivable balance with accounts receivable balances of $ 18,757 and $ 7,734 , respectively, as of March 31, 2023 , and two customers each represented more than 10% of the Company's net accounts receivable balance with accounts receivable balances of $ 22,641 and $ 9,861 , respectively, as of December 31, 2022. The Company also rents products directly to consumers for insurance reimbursement, which resulted in a customer concentration relating to Medicare’s service reimbursement programs. Medicare’s service reimbursement programs accounted for 73.8 % and 79.0 % of rental revenue in the three months ended March 31, 2023 and 2022 , respectively, and based on total revenue were 16.6 % and 12.8 % for the three months ended March 31, 2023 and 2022 , respectively. Accounts receivable balances relating to Medicare’s service reimbursement programs (including held and unbilled, net of allowances) amounted to $ 3,039 or 5.6 % of total net accounts receivable as of March 31, 2023 compared to $ 2,138 or 3.4 % of total net accounts receivable as of December 31, 2022. The Company currently purchases raw materials from a limited number of vendors, which resulted in a concentration of three major vendors. The three major vendors supply the Company with raw materials used to manufacture the Company’s products. For the three months ended March 31, 2023 , the Company’s three major vendors accounted for 34.1 %, 13.1 % and 7.3 %, respectively, of total raw material purchases. For the three months ended March 31, 2022 , the Company’s three major vendors accounted for 25.2 %, 19.9 % and 8.4 %, respectively, of total raw material purchases. A portion of revenue is earned from sales outside the United States. Approximately 77.0 % and 73.2 % of the non-U.S. revenue for the three months ended March 31, 2023 and 2022, respectively, were invoiced in Euros. A breakdown of the Company’s revenue from U.S. and non-U.S. sources for the three months ended March 31, 2023 and 2022, respectively, is as follows: Three months ended 2023 2022 U.S. revenue $ 53,190 $ 52,444 Non-U.S. revenue 18,972 27,941 Total revenue $ 72,162 $ 80,385 Inventories Inventories are stated at the lower of cost and net realizable value, using the first-in, first-out (FIFO) method. The Company records adjustments at least quarterly to inventory for potentially excess, obsolete, slow-moving or impaired items. The Company recorded noncurrent inventory related to inventories that are expected to be realized or consumed after one year of $ 1,296 and $ 1,249 as of March 31, 2023 and December 31, 2022 , respectively. Noncurrent inventories are primarily related to raw materials purchased in bulk to support long-term expected repairs to reduce costs and are classified in other assets. The Company had prepayments for raw materials of $ 3,041 and $ 7,017 as of March 31, 2023 and December 31, 2022, respectively, that were classified in prepaid expenses and other current assets. During the three months ended March 31, 2023 and 2022 , $ 1,013 and $ 533 , respectively, of inventory was transferred to rental equipment and was considered a noncash transaction in the production and purchase of rental equipment on the consolidated statements of cash flows. Inventories that are considered current consist of the following: March 31, December 31, 2023 2022 Raw materials and work-in-progress $ 25,689 $ 26,496 Finished goods 14,291 9,324 Less: reserves ( 1,158 ) ( 1,727 ) Inventories, net $ 38,822 $ 34,093 Property and equipment Repair and maintenance expense, which includes labor, parts and freight, for rental equipment was $ 1,311 and $ 1,030 for the three months ended March 31, 2023 and 2022, respectively. Depreciation and amortization expense related to rental equipment and other property and equipment are summarized below for the three months ended March 31, 2023 and 2022, respectively. Three months ended 2023 2022 Rental equipment $ 3,078 $ 2,638 Other property and equipment 982 975 Total depreciation and amortization $ 4,060 $ 3,613 Property and equipment and rental equipment with associated accumulated depreciation is summarized below as of March 31, 2023 and December 31, 2022, respectively. March 31, December 31, Property and equipment 2023 2022 Rental equipment, net of allowances of $ 2,765 and $ 2,255 , respectively $ 63,250 $ 61,679 Other property and equipment 34,507 33,434 Property and equipment 97,757 95,113 Accumulated depreciation Rental equipment 30,363 31,320 Other property and equipment 21,452 20,524 Accumulated depreciation 51,815 51,844 Property and equipment, net Rental equipment, net of allowances of $2,765 and $2,255, respectively 32,887 30,359 Other property and equipment 13,055 12,910 Property and equipment, net $ 45,942 $ 43,269 Long-lived assets The Company accounts for the impairment and disposition of long-lived assets in accordance with Accounting Standards Codification (ASC) 360 — Property, Plant, and Equipment . In accordance with ASC 360, long-lived assets to be held are reviewed for events or changes in circumstances that indicate that their carrying value may not be recoverable. No impairments were recorded as of March 31, 2023 and March 31, 2022. Goodwill The changes in the carrying amount of goodwill for the three months ended March 31, 2023 were as follows: Balance as of December 31, 2022 $ 32,852 Translation adjustment 35 Balance as of March 31, 2023 $ 32,887 As of March 31, 2023 , the Company had no accumulated impairment losses related to goodwill. Current liabilities Accounts payable and accrued expenses as of March 31, 2023 and December 31, 2022 consisted of the following: March 31, December 31, 2023 2022 Accounts payable $ 18,043 $ 18,237 Accrued inventory (in-transit and unvouchered receipts) and trade payables 8,688 10,837 Accrued purchasing card liability 3,459 2,606 Accrued franchise, sales and use taxes 480 492 Other accrued expenses 1,513 1,802 Accounts payable and accrued expenses $ 32,183 $ 33,974 Accrued payroll as of March 31, 2023 and December 31, 2022 consisted of the following: March 31, December 31, 2023 2022 Accrued bonuses $ 2,076 $ 2,620 Accrued wages and other payroll related items 5,043 4,967 Accrued vacation 3,449 3,133 Accrued employee stock purchase plan deductions 189 470 Accrued payroll $ 10,757 $ 11,190

Leases

Leases	3 Months Ended
	Mar. 31, 2023
Leases [Abstract]
Leases	5. Leases The Company has entered into operating leases primarily for commercial buildings. These leases have terms which range from 3 years to 11 years , some of which include options to extend the leases for up to 5 years . Rent expense, including short-term lease cost, was $ 972 and $ 971 for the three months ended March 31, 2023 and 2022, respectively. Information related to the Company's right-of-use assets and related operating lease liabilities were as follows: Three months ended March 31, 2023 2022 Cash paid for operating lease liabilities $ 994 $ 1,008 Operating lease cost 957 975 Non-cash right-of-use assets obtained in exchange for new operating lease obligations 264 — Weighted average remaining lease term 2.1 years 2.7 years Weighted average discount rate 3.0 % 2.9 % Maturities of lease liabilities due in the 12-month period ending March 31, 2024 $ 4,002 2025 3,464 2026 2,787 2027 2,803 2028 2,842 Thereafter 8,675 24,573 Less imputed interest ( 1,824 ) Total lease liabilities $ 22,749 Operating lease liability - current $ 3,570 Operating lease liability - noncurrent $ 19,179 Total lease liabilities $ 22,749

Earnings (Loss) per Share

Earnings (Loss) per Share	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Earnings (Loss) per Share	6. Earnings (loss) per share Earnings (loss) per share (EPS) is computed in accordance with ASC 260 —Earnings per Share and is calculated using the weighted average number of common shares outstanding during each period. Diluted EPS assumes the conversion, exercise or issuance of all potential common stock equivalents (which can include dilution of outstanding stock options, restricted stock units and restricted stock awards) unless the effect is to reduce a loss or increase the income per share. For purposes of this calculation, common stock subject to repurchase by the Company, options, and other dilutive awards are considered to be common stock equivalents and are only included in the calculation of diluted earnings (loss) per share when their effect is dilutive. The computation of EPS is as follows: Three months ended 2023 2022 Numerator—basic and diluted: Net loss $ ( 20,349 ) $ ( 14,214 ) Denominator: Weighted average common shares - basic common stock (1) 23,009,617 22,754,421 Weighted average common shares - diluted common stock (2) 23,009,617 22,754,421 Net loss per share - basic common stock $ ( 0.88 ) $ ( 0.62 ) Net loss per share - diluted common stock (2) $ ( 0.88 ) $ ( 0.62 ) Denominator calculation from basic to diluted: Weighted average common shares - basic common stock (1) 23,009,617 22,754,421 Stock options and other dilutive awards 228,281 88,193 Weighted average common shares - diluted common stock 23,237,898 22,842,614 Shares excluded from diluted weighted average shares: Stock options 286,861 380,890 Restricted stock units and restricted stock awards 491,406 577,242 Shares excluded from diluted weighted average shares 778,267 958,132 (1) Unvested restricted stock units and restricted stock awards are not included as shares outstanding in the calculation of basic earnings per share. Vested restricted stock units and restricted stock awards are included in basic earnings per share if all vesting and performance criteria have been met. Performance-based restricted stock units and restricted stock awards are included in the number of shares used to calculate diluted earnings per share as long as all applicable performance criteria are met, and their effect is dilutive. Restricted stock awards are eligible to receive all dividends declared on the Company’s common shares during the vesting period; however, such dividends are not paid until the restrictions lapse. (2) Due to net losses for the three months ended March 31, 2023 and March 31, 2022 , diluted loss per share is the same as basic.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Income Taxes	7. Income taxes The Company accounts for income taxes in accordance with ASC 740 — Income Taxes . Under ASC 740, income taxes are recognized for the amount of taxes payable or refundable for the current period and deferred tax liabilities and assets are recognized for the future tax consequences of transactions that have been recognized in the Company’s consolidated financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided when it is more likely than not that some portion, or all, of the deferred tax asset will not be realized. As of December 31, 2022, the Company recorded a full valuation allowance of $ 41,933 . As of March 31, 2023, t he Company continued to record a valuation allowance against its deferred tax assets. The Company accounts for uncertainties in income taxes in accordance with ASC 740-10 — Accounting for Uncertainty in Income Taxes . ASC 740-10 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. This accounting standard also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company recognizes interest and penalties on taxes, if any, within its income tax provision on its consolidated statements of comprehensive loss.

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2023
Equity [Abstract]
Stockholders' Equity	8. Stockholders’ equity The Company has a 2012 Equity Incentive Plan (2012 Plan) under which the Company granted options to purchase shares of its common stock. As of March 31, 2023 , options to purchase 2,866 shares of common stock remained outstanding under the 2012 Plan. The 2012 Plan was terminated in connection with the Company’s initial public offering in February 2014, and accordingly, no new options are available for issuance under this plan. The 2012 Plan continues to govern outstanding awards granted thereunder. The Company has a 2014 Equity Incentive Plan (2014 Plan) that provides for the grant of incentive stock options, within the meaning of Section 422 of the Internal Revenue Code, to the Company’s employees and any parent and subsidiary corporation’s employees, and for the grant of nonstatutory stock options, restricted stock, restricted stock units, restricted stock awards, stock appreciation rights, performance units and performance shares to its employees, directors and consultants and its parent and subsidiary corporations’ employees and consultants. As of March 31, 2023 , awards with respect to 1,931,076 shares of the Company’s common stock were outstanding, and 691,309 shares of common stock remained available for issuance under the 2014 Plan. The shares available for issuance under the 2014 Plan will be increased by any shares returned to the 2012 Plan and 2014 Plan as a result of expiration or termination of awards (provided that the maximum number of shares that may be added to the 2014 Plan pursuant to such previously granted awards under the 2012 Plan is 2,328,569 shares). The number of shares available for issuance under the 2014 Plan also is increased annually on the first day of each fiscal year by an amount equal to the least of: • 895,346 shares; • 4 % of the outstanding shares of common stock as of the last day of the Company’s immediately preceding fiscal year; or • such other amount as the Company’s board of directors may determine. For 2023 , an additional 895,346 shares were added to the 2014 Plan share reserve pursuant to the provision described above. Stock options Options typically expire between seven and ten years from the date of grant and vest over one to four year terms. Options have been granted to employees, directors and consultants of the Company, as determined by the board of directors, at the deemed fair market value of the shares underlying the options at the date of grant. The activity for stock options under the Company’s stock plans for the three months ended March 31, 2023 is as follows: Remaining weighted- Weighted- average Per share average contractual average Price per exercise terms intrinsic Options share price (in years) value Outstanding as of December 31, 2022 348,284 $ 1.17 -$ 83.30 $ 44.21 0.43 $ 2.07 Exercised ( 54,432 ) 1.17 - 8.37 7.03 Forfeited ( 4,125 ) 44.19 44.19 Outstanding as of March 31, 2023 289,727 8.37 - 83.30 51.19 0.22 0.04 Vested and exercisable as of March 31, 2023 289,727 8.37 - 83.30 51.19 0.22 0.04 Vested and expected to vest as of March 31, 2023 289,727 $ 8.37 -$ 83.30 $ 51.19 0.22 $ 0.04 The total intrinsic value of options exercised during the three months ended March 31, 2023 and 2022 was $ 735 and $ 84 , respectively. As of March 31, 2023, all stock-based compensation expense for options granted under the Plans was recognized. Stock incentive awards The Company grants restricted stock units (RSUs) and restricted stock awards (RSAs) under the 2014 Plan (Stock Awards). The Stock Awards vest either based solely on the satisfaction of time-based service conditions or on the satisfaction of time-based service conditions combined with performance criteria. Stock Awards are subject to forfeiture if the holder’s services to the Company terminate before vesting. Stock Awards granted with only time-based service vesting conditions generally vest over three-year and four-year service periods, as defined in the terms of each award. Stock Awards that vest based on the satisfaction of time-based service conditions combined with performance criteria generally vest over a three-year service and performance period, based on performance criteria established at the time of the award. The portion of the Stock Award that is earned may equal or be less than the targeted number of shares subject to the Stock Award depending on whether the performance criteria are met. Stock Awards activity for the three months ended March 31, 2023 is summarized below: Weighted- average grant Performance date fair and value Restricted stock units Time-based time-based Total per share Unvested restricted stock units as of December 31, 2022 820,941 183,197 1,004,138 $ 32.72 Granted 670,317 536,990 1,207,307 15.84 Vested ( 90,677 ) ( 15,618 ) ( 106,295 ) 38.36 Forfeited/canceled ( 80,175 ) ( 60,904 ) ( 141,079 ) 31.10 Unvested restricted stock units as of March 31, 2023 (1) 1,320,406 643,665 1,964,071 $ 22.82 Unvested and expected to vest restricted stock units outstanding as of March 31, 2023 1,475,786 $ 23.12 Weighted- average grant Performance date fair and value Restricted stock awards Time-based time-based Total per share Unvested restricted stock awards outstanding as of December 31, 2022 786 — 786 $ 59.55 Vested ( 495 ) — ( 495 ) 69.32 Unvested restricted stock awards outstanding as of March 31, 2023 (1) 291 — 291 $ 42.93 Unvested and expected to vest restricted stock awards outstanding as of March 31, 2023 272 $ 42.93 (1) Outstanding restricted stock units and restricted stock awards are based on the maximum payout of the targeted number of shares. As of March 31, 2023 , the unrecognized compensation cost related to unvested employee restricted stock units and restricted stock awards was $ 28,329 , excluding estimated forfeitures. This amount is expected to be recognized over a weighted average period of 2.4 years. Employee stock purchase plan The Company’s 2014 Employee Stock Purchase Plan (ESPP) provides for the grant to all eligible employees an option to purchase stock under the ESPP, within the meaning Section 423 of the Internal Revenue Code. The ESPP permits participants to purchase common stock through payroll deductions of up to 15 % of their eligible compensation, which includes a participant’s base straight time gross earnings, incentive compensation, bonuses, overtime and shift premium, but exclusive of payments for equity compensation and other similar compensation. A participant may purchase a maximum of 1,500 shares during a purchase period. Amounts deducted and accumulated by the participant are used to purchase shares of the Company’s common stock at the end of each six-month period. The purchase price of the shares will be 85 % of the lower of the fair market value of the Company’s common stock on the first trading day of each offering period or on the exercise date. The offering periods are currently approximately six months in length beginning on the first business day on or after March 1 and September 1 of each year and ending on the first business day on or after September 1 and March 1 approximately six months later. As of March 31, 2023 , a total of 638,951 shares of common stock were available for sale pursuant to the ESPP. The number of shares available for sale under the ESPP is increased annually on the first day of each fiscal year by an amount equal to the least of: • 179,069 shares; • 1.5 % of the outstanding shares of the Company’s common stock on the last day of the Company’s immediately preceding fiscal year; or • such other amount as may be determined by the administrator. For 2023 , an additional 179,069 shares were added to the ESPP share reserve pursuant to the provision described above. Stock-based compensation Stock-based compensation expense recognized for the three months ended March 31, 2023 and 2022, was as follows: Three months ended March 31, 2023 2022 Stock-based compensation expense by type of award: Restricted stock units and restricted stock awards $ 3,305 $ 2,468 Employee stock purchase plan 137 197 Total stock-based compensation expense $ 3,442 $ 2,665 Employee stock-based compensation expense was calculated based on awards of stock options, restricted stock units and restricted stock awards ultimately expected to vest based on the Company’s historical award cancellations. ASC 718 – Compensation-Stock Compensation requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. For the three months ended March 31, 2023 and 2022, respectively, stock-based compensation expense recognized under ASC 718, included in cost of revenue, research and development expense, sales and marketing expense, and general and administrative expense was as follows: Three months ended March 31, 2023 2022 Cost of revenue $ 84 $ 233 Research and development 458 384 Sales and marketing 774 591 General and administrative 2,126 1,457 Total stock-based compensation expense $ 3,442 $ 2,665

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	9. Commitments and contingencies Purchase obligations The Company had approximately $ 111,400 of outstanding purchase orders due within one year with its outside vendors and suppliers as of March 31, 2023. Warranty obligation The following table identifies the changes in the Company’s aggregate product warranty liabilities for the three and twelve-month periods ended March 31, 2023 and December 31, 2022, respectively: March 31, December 31, 2023 2022 Product warranty liability at beginning of period $ 19,913 $ 13,726 Accruals for warranties issued 1,681 10,416 Adjustments related to preexisting warranties 1,540 8,234 Settlements made (in cash or in kind) ( 3,041 ) ( 12,463 ) Product warranty liability at end of period $ 20,093 $ 19,913 Contract liabilities Contract liabilities primarily consist of deferred revenue related to lifetime warranties on direct-to-consumer sales revenue when cash payments are received in advance of services performed under the contract. The contract with the customer states the final terms of the sale, including the description, quantity, and price of each product or service purchase. The decrease in deferred revenue related to lifetime warranties for the three months ended March 31, 2023 was primarily driven by $ 1,674 of revenue recognized that were included in the deferred revenue balances as of December 31, 2022 , partially offset by $ 869 of payments received in advance of satisfying performance obligations. Deferred revenue related to lifetime warranties was $ 15,729 and $ 16,534 as of March 31, 2023 and December 31, 2022, respectively, and is classified within deferred revenue - current and noncurrent deferred revenue in the consolidated balance sheet. Legislation and HIPAA The healthcare industry is subject to numerous laws and regulations of federal, state and local governments. These laws and regulations include, but are not necessarily limited to, matters such as licensure, accreditation, government healthcare program participation requirements, reimbursement for patient services, and Medicare and Medicaid fraud and abuse. Compliance with government laws and regulations can be subject to future government review and interpretation as well as regulatory actions unknown or unasserted at this time. The Health Insurance Portability and Accountability Act of 1996 (HIPAA) was enacted to ensure health insurance portability, reduce healthcare fraud and abuse, guarantee security and privacy of health information, and enforce standards for health information. The Health Information Technology for Economic and Clinical Health Act (HITECH Act), in part, imposes notification requirements of certain security breaches relating to protected health information. The Company is not aware of any pending claims against it under the HIPAA and HITECH regulations that are applicable to the Company’s business. Legal proceedings Civil Investigative Demand On June 21, 2022, the Company received a civil investigative demand (CID) from the United States Attorney’s Office for the Northern District of Iowa. The CID states that it was issued in a False Claims Act investigation to determine whether there is or has been a violation of the False Claims Act and that the investigation involves concerns of inappropriate kickbacks provided by certain manufacturers of portable oxygen concentrators and related products in violation of the Anti-Kickback Statute. The CID followed informal requests from the United States Attorney’s Office for the Northern District of Iowa begun in late 2020, with which the Company voluntarily complied, to obtain information concerning the Company’s participation in (i) zero-interest or below market-rate loans through a third party lender to finance customer purchases; (ii) guaranteeing the obligation of a customer to a finance company in connection with financing of purchases of Company equipment; and (iii) entering into an agreement with a customer that included marketing, exclusivity, discount, and favorable financing terms. The Company is cooperating in the investigation. The Company is currently unable to predict the outcome of this investigation or whether qui tam or other litigation is probable. Regardless of the outcome, this inquiry has the potential to have an adverse impact on the Company due to any related defense and settlement costs, diversion of management resources, and other factors. Other Litigation The Company is party to various legal proceedings arising in the normal course of business. The Company carries insurance, subject to specified deductibles under the policies, to protect against losses from certain types of legal claims. At this time, the Company does not anticipate that any of these other proceedings arising in the normal course of business will have a material adverse effect on the Company’s business. Regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources, and other factors.

Restructuring Charges

Restructuring Charges	3 Months Ended
	Mar. 31, 2023
Restructuring and Related Activities [Abstract]
Restructuring Charges	10. Restructuring charges The Company incurred $ 1,809 of restructuring costs during the three months ended March 31, 2023, primarily in connection with the Company's cost reduction initiatives, which were recorded within general and administrative expense in the consolidated statements of loss. The restructuring charges consisted primarily of severance and termination benefits. Other related costs consisted of targeted workforce reductions, centralizing manufacturing activities, equipment relocation and outsourcing.

Foreign Currency Exchange Contr

Foreign Currency Exchange Contracts and Hedging	3 Months Ended
	Mar. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Foreign currency exchange contracts and hedging	11. Foreign currency exchange contracts and hedging As of March 31, 2023 and March 31, 2022 , the Company’s total non-designated and designated derivative contracts had notional amounts totaling approximately $ 8,041 and $ 2,445 , respectively, and $ 0 and $ 1,704 , respectively. These contracts were comprised of offsetting contracts with the same counterparty, each expires within one month . During the three months ended March 31, 2023 and 2022 , these contracts had, net of tax, an unrealized loss of $ 0 and $ 74 , respectively. The nonperformance risk of the Company and the counterparty did not have a material impact on the fair value of the derivatives. During the three months ended March 31, 2023 and 2022,there were no ineffective portions relating to these hedges and the hedges remained effective through their respective settlement dates. As of March 31, 2023 , the Company had no designated hedges and one non-designated hedge. As of March 31, 2022 , the Company had eight designated hedges and one non-designated hedge.

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Basis of Consolidation	Basis of consolidation The consolidated financial statements include the accounts of Inogen, Inc. and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated.
Use of Estimates	Use of estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases these estimates and assumptions upon historical experience, existing and known circumstances, authoritative accounting pronouncements and other factors that management believes to be reasonable. Significant areas requiring the use of management estimates relate to revenue recognition, warranty reserves and expense, determining the stand-alone selling price (SSP) and service period of performance obligations, rental asset valuations and write-downs, accounts receivable allowances for bad debts, returns and adjustments, impairment of goodwill, impairment of long-lived assets, stock-based compensation expense, and income taxes. Actual results could differ from these estimates.
Restructuring charges	Restructuring charges Restructuring costs include workforce reductions, termination benefits, centralizing manufacturing activities, outsourcing, contract termination, and equipment relocation. Key assumptions used in calculating the restructuring costs include the terms of, and payments under, agreements to terminate certain contractual obligations and the timing of reductions in workforce

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Summary of Fair Value Assets Measured on Recurring Basis for Cash, Cash Equivalents and Marketable Securities	The following table summarizes fair value measurements by level for the assets measured at fair value on a recurring basis for cash, cash equivalents and marketable securities: As of March 31, 2023 Gross Cash Adjusted unrealized and cash Marketable cost gains Fair value equivalents securities Cash $ 23,864 $ — $ 23,864 $ 23,864 $ — Level 1: Money market accounts 99,048 — 99,048 99,048 — Level 2: Corporate bonds 5,985 — 5,985 5,985 — U.S. Treasury securities 25,253 95 25,348 14,920 10,428 Institutional Insured Liquidity Deposit Savings 20,320 — 20,320 20,320 — Total $ 174,470 $ 95 $ 174,565 $ 164,137 $ 10,428 As of December 31, 2022 Gross Cash Adjusted unrealized and cash cost gains Fair value equivalents Cash $ 27,970 $ — $ 27,970 $ 27,970 Level 1: Money market accounts 113,534 — 113,534 113,534 Level 2: Corporate bonds 6,474 — 6,474 6,474 U.S. Treasury securities 18,913 26 18,939 18,939 Institutional Insured Liquidity Deposit Savings 20,097 — 20,097 20,097 Total $ 186,988 $ 26 $ 187,014 $ 187,014
Summary of Components of Accumulated Other Comprehensive Income (Loss)	The components of accumulated other comprehensive income (loss) were as follows: Foreign Unrealized Accumulated currency gains other translation on marketable comprehensive adjustments securities income (loss) Balance as of December 31, 2022 $ ( 269 ) $ 26 $ ( 243 ) Other comprehensive income 170 69 239 Balance as of March 31, 2023 $ ( 99 ) $ 95 $ ( 4 )

Balance Sheet Components (Table

Balance Sheet Components (Tables)	3 Months Ended
	Mar. 31, 2023
Balance Sheet Related Disclosures [Abstract]
Summary of Cash, Cash Equivalents and Short-term Investments	Cash, cash equivalents and marketable securities consist of the following: March 31, December 31, Cash and cash equivalents 2023 2022 Cash $ 23,864 $ 27,970 Money market accounts 99,048 113,534 Corporate bonds 5,985 6,474 U.S. Treasury securities 14,920 18,939 Institutional Insured Liquidity Deposit Savings 20,320 20,097 Total cash and cash equivalents $ 164,137 $ 187,014 Marketable securities U.S. Treasury securities 10,428 — Total marketable securities $ 10,428 $ —
Schedule of Net Accounts Receivable Balance Concentrations by Major Category	Net accounts receivable (gross accounts receivable, net of allowances) balance concentrations by major category as of March 31, 2023 and December 31, 2022 were as follows: March 31, December 31, Net accounts receivable 2023 2022 Rental (1) $ 7,392 $ 5,246 Business-to-business and other receivables (2) 46,493 57,479 Total net accounts receivable $ 53,885 $ 62,725 (1) Rental includes Medicare, Medicaid/other government, private insurance and patient pay. (2) Business-to-business receivables included extended terms for two customers: 1) One customer had accounts receivable balances of $ 7,734 and $ 9,861 as of March 31, 2023 and December 31, 2022 , respectively. The customer received extended payment terms through a direct financing plan offered. The Company also has a credit insurance policy in place, which allocated up to $ 12,000 in coverage as of March 31, 2023 and December 31, 2022 , for this customer with a $ 400 deductible and 10 % retention; and 2) One customer had an accounts receivable balance of $ 18,757 and $ 22,641 as of March 31, 2023 and December 31, 2022.
Schedule of Allowances for Accounts Receivable	The following table sets forth the accounts receivable allowances as of March 31, 2023 and December 31, 2022: March 31, December 31, Allowances - accounts receivable 2023 2022 Doubtful accounts $ 156 $ 77 Sales returns 699 483 Total allowances - accounts receivable $ 855 $ 560
Breakdown of Company's Revenue from U.S. and Non-U.S. Sources	A portion of revenue is earned from sales outside the United States. Approximately 77.0 % and 73.2 % of the non-U.S. revenue for the three months ended March 31, 2023 and 2022, respectively, were invoiced in Euros. A breakdown of the Company’s revenue from U.S. and non-U.S. sources for the three months ended March 31, 2023 and 2022, respectively, is as follows: Three months ended 2023 2022 U.S. revenue $ 53,190 $ 52,444 Non-U.S. revenue 18,972 27,941 Total revenue $ 72,162 $ 80,385
Schedule of Inventories	Inventories that are considered current consist of the following: March 31, December 31, 2023 2022 Raw materials and work-in-progress $ 25,689 $ 26,496 Finished goods 14,291 9,324 Less: reserves ( 1,158 ) ( 1,727 ) Inventories, net $ 38,822 $ 34,093
Summary of Depreciation and Amortization Expense of Rental Equipment and Other Property and Equipment	Depreciation and amortization expense related to rental equipment and other property and equipment are summarized below for the three months ended March 31, 2023 and 2022, respectively. Three months ended 2023 2022 Rental equipment $ 3,078 $ 2,638 Other property and equipment 982 975 Total depreciation and amortization $ 4,060 $ 3,613
Summary of Property Plant and Equipment and Rental Equipment with Associated Accumulated Depreciation	Property and equipment and rental equipment with associated accumulated depreciation is summarized below as of March 31, 2023 and December 31, 2022, respectively. March 31, December 31, Property and equipment 2023 2022 Rental equipment, net of allowances of $ 2,765 and $ 2,255 , respectively $ 63,250 $ 61,679 Other property and equipment 34,507 33,434 Property and equipment 97,757 95,113 Accumulated depreciation Rental equipment 30,363 31,320 Other property and equipment 21,452 20,524 Accumulated depreciation 51,815 51,844 Property and equipment, net Rental equipment, net of allowances of $2,765 and $2,255, respectively 32,887 30,359 Other property and equipment 13,055 12,910 Property and equipment, net $ 45,942 $ 43,269
Schedule of Changes in Carrying Amount of Goodwill	The changes in the carrying amount of goodwill for the three months ended March 31, 2023 were as follows: Balance as of December 31, 2022 $ 32,852 Translation adjustment 35 Balance as of March 31, 2023 $ 32,887
Schedule of Accounts Payable and Accrued Expenses	Accounts payable and accrued expenses as of March 31, 2023 and December 31, 2022 consisted of the following: March 31, December 31, 2023 2022 Accounts payable $ 18,043 $ 18,237 Accrued inventory (in-transit and unvouchered receipts) and trade payables 8,688 10,837 Accrued purchasing card liability 3,459 2,606 Accrued franchise, sales and use taxes 480 492 Other accrued expenses 1,513 1,802 Accounts payable and accrued expenses $ 32,183 $ 33,974
Schedule of Accrued Payroll	Accrued payroll as of March 31, 2023 and December 31, 2022 consisted of the following: March 31, December 31, 2023 2022 Accrued bonuses $ 2,076 $ 2,620 Accrued wages and other payroll related items 5,043 4,967 Accrued vacation 3,449 3,133 Accrued employee stock purchase plan deductions 189 470 Accrued payroll $ 10,757 $ 11,190

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2023
Leases [Abstract]
Schedule of Right-of-Use Assets and Operating Lease Liabilities	Information related to the Company's right-of-use assets and related operating lease liabilities were as follows: Three months ended March 31, 2023 2022 Cash paid for operating lease liabilities $ 994 $ 1,008 Operating lease cost 957 975 Non-cash right-of-use assets obtained in exchange for new operating lease obligations 264 — Weighted average remaining lease term 2.1 years 2.7 years Weighted average discount rate 3.0 % 2.9 %
Schedule of Maturities of Lease Liabilities	Maturities of lease liabilities due in the 12-month period ending March 31, 2024 $ 4,002 2025 3,464 2026 2,787 2027 2,803 2028 2,842 Thereafter 8,675 24,573 Less imputed interest ( 1,824 ) Total lease liabilities $ 22,749 Operating lease liability - current $ 3,570 Operating lease liability - noncurrent $ 19,179 Total lease liabilities $ 22,749

Earnings (Loss) per Share (Tabl

Earnings (Loss) per Share (Tables)	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Computation of Earnings Per Share	The computation of EPS is as follows: Three months ended 2023 2022 Numerator—basic and diluted: Net loss $ ( 20,349 ) $ ( 14,214 ) Denominator: Weighted average common shares - basic common stock (1) 23,009,617 22,754,421 Weighted average common shares - diluted common stock (2) 23,009,617 22,754,421 Net loss per share - basic common stock $ ( 0.88 ) $ ( 0.62 ) Net loss per share - diluted common stock (2) $ ( 0.88 ) $ ( 0.62 ) Denominator calculation from basic to diluted: Weighted average common shares - basic common stock (1) 23,009,617 22,754,421 Stock options and other dilutive awards 228,281 88,193 Weighted average common shares - diluted common stock 23,237,898 22,842,614 Shares excluded from diluted weighted average shares: Stock options 286,861 380,890 Restricted stock units and restricted stock awards 491,406 577,242 Shares excluded from diluted weighted average shares 778,267 958,132 (1) Unvested restricted stock units and restricted stock awards are not included as shares outstanding in the calculation of basic earnings per share. Vested restricted stock units and restricted stock awards are included in basic earnings per share if all vesting and performance criteria have been met. Performance-based restricted stock units and restricted stock awards are included in the number of shares used to calculate diluted earnings per share as long as all applicable performance criteria are met, and their effect is dilutive. Restricted stock awards are eligible to receive all dividends declared on the Company’s common shares during the vesting period; however, such dividends are not paid until the restrictions lapse. (2) Due to net losses for the three months ended March 31, 2023 and March 31, 2022 , diluted loss per share is the same as basic.

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2023
Equity [Abstract]
Summary of Stock Options Activity	The activity for stock options under the Company’s stock plans for the three months ended March 31, 2023 is as follows: Remaining weighted- Weighted- average Per share average contractual average Price per exercise terms intrinsic Options share price (in years) value Outstanding as of December 31, 2022 348,284 $ 1.17 -$ 83.30 $ 44.21 0.43 $ 2.07 Exercised ( 54,432 ) 1.17 - 8.37 7.03 Forfeited ( 4,125 ) 44.19 44.19 Outstanding as of March 31, 2023 289,727 8.37 - 83.30 51.19 0.22 0.04 Vested and exercisable as of March 31, 2023 289,727 8.37 - 83.30 51.19 0.22 0.04 Vested and expected to vest as of March 31, 2023 289,727 $ 8.37 -$ 83.30 $ 51.19 0.22 $ 0.04
Summary of Restricted Stock Activity	Stock Awards activity for the three months ended March 31, 2023 is summarized below: Weighted- average grant Performance date fair and value Restricted stock units Time-based time-based Total per share Unvested restricted stock units as of December 31, 2022 820,941 183,197 1,004,138 $ 32.72 Granted 670,317 536,990 1,207,307 15.84 Vested ( 90,677 ) ( 15,618 ) ( 106,295 ) 38.36 Forfeited/canceled ( 80,175 ) ( 60,904 ) ( 141,079 ) 31.10 Unvested restricted stock units as of March 31, 2023 (1) 1,320,406 643,665 1,964,071 $ 22.82 Unvested and expected to vest restricted stock units outstanding as of March 31, 2023 1,475,786 $ 23.12 Weighted- average grant Performance date fair and value Restricted stock awards Time-based time-based Total per share Unvested restricted stock awards outstanding as of December 31, 2022 786 — 786 $ 59.55 Vested ( 495 ) — ( 495 ) 69.32 Unvested restricted stock awards outstanding as of March 31, 2023 (1) 291 — 291 $ 42.93 Unvested and expected to vest restricted stock awards outstanding as of March 31, 2023 272 $ 42.93 (1) Outstanding restricted stock units and restricted stock awards are based on the maximum payout of the targeted number of shares.
Summary of Stock-based Compensation Expense	Stock-based compensation expense recognized for the three months ended March 31, 2023 and 2022, was as follows: Three months ended March 31, 2023 2022 Stock-based compensation expense by type of award: Restricted stock units and restricted stock awards $ 3,305 $ 2,468 Employee stock purchase plan 137 197 Total stock-based compensation expense $ 3,442 $ 2,665 For the three months ended March 31, 2023 and 2022, respectively, stock-based compensation expense recognized under ASC 718, included in cost of revenue, research and development expense, sales and marketing expense, and general and administrative expense was as follows: Three months ended March 31, 2023 2022 Cost of revenue $ 84 $ 233 Research and development 458 384 Sales and marketing 774 591 General and administrative 2,126 1,457 Total stock-based compensation expense $ 3,442 $ 2,665

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Schedule of Changes in Aggregate Product Warranty Liabilities	The following table identifies the changes in the Company’s aggregate product warranty liabilities for the three and twelve-month periods ended March 31, 2023 and December 31, 2022, respectively: March 31, December 31, 2023 2022 Product warranty liability at beginning of period $ 19,913 $ 13,726 Accruals for warranties issued 1,681 10,416 Adjustments related to preexisting warranties 1,540 8,234 Settlements made (in cash or in kind) ( 3,041 ) ( 12,463 ) Product warranty liability at end of period $ 20,093 $ 19,913

Business Overview - Additional

Business Overview - Additional Information (Details)	3 Months Ended
	Mar. 31, 2023
Inogen Europe Holding B.V.
Business Overview Disclosures [Line Items]
Date of incorporation of subsidiary	Apr. 13, 2017

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Fair Value Assets Measured on Recurring Basis for Cash, Cash Equivalents and Marketable Securities (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 164,137	$ 187,014
Fair Value Measurements Recurring
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Adjusted cost	174,470	186,988
Gross unrealized gains	95	26
Fair value	174,565	187,014
Cash and cash equivalents	164,137	187,014
Marketable securities	10,428
Fair Value Measurements Recurring | Cash
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Adjusted cost	23,864	27,970
Fair value	23,864	27,970
Cash and cash equivalents	23,864	27,970
Fair Value Measurements Recurring | Level 1 | Money Market Accounts
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Adjusted cost	99,048	113,534
Fair value	99,048	113,534
Cash and cash equivalents	99,048	113,534
Fair Value Measurements Recurring | Fair Value, Inputs, Level 2 | Corporate Bonds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Adjusted cost	5,985	6,474
Fair value	5,985	6,474
Cash and cash equivalents	5,985	6,474
Fair Value Measurements Recurring | Fair Value, Inputs, Level 2 | U.S. Treasury Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Adjusted cost	25,253	18,913
Gross unrealized gains	95	26
Fair value	25,348	18,939
Cash and cash equivalents	14,920	18,939
Marketable securities	10,428
Fair Value Measurements Recurring | Fair Value, Inputs, Level 2 | Institutional Insured Liquidity Deposit Savings
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Adjusted cost	20,320	20,097
Fair value	20,320	20,097
Cash and cash equivalents	$ 20,320	$ 20,097

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Forward Contracts
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Related payable	$ 203	$ 422

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Components of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning Balance	$ 297,406	$ 370,227
Other comprehensive income (loss)	239	(285)
Ending Balance	281,297	358,285
Foreign Currency Translation Adjustments
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning Balance	(269)
Other comprehensive income (loss)	170
Ending Balance	(99)
Unrealized Gains on Marketable Securities
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning Balance	26
Other comprehensive income (loss)	69
Ending Balance	95
Accumulated other comprehensive income (loss)
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning Balance	(243)	1,469
Other comprehensive income (loss)	239	(285)
Ending Balance	$ (4)	$ 1,184

Balance Sheet Components - Summ

Balance Sheet Components - Summary of Cash, Cash Equivalents and Short-term Investments (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Cash and cash equivalents
Cash	$ 23,864	$ 27,970
Money market accounts	99,048	113,534
Corporate bonds	5,985	6,474
U.S. Treasury securities	14,920	18,939
Institutional Insured Liquidity Deposit Savings	20,320	20,097
Total cash and cash equivalents	164,137	$ 187,014
Marketable securities
Marketable securities	10,428
U.S. Treasury Securities
Marketable securities
Marketable securities	$ 10,428

Balance Sheet Components - Sche

Balance Sheet Components - Schedule of Net Accounts Receivable Balance Concentrations by Major Category (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Accounts Notes And Loans Receivable [Line Items]
Net accounts receivable	$ 53,885	$ 62,725
Rental
Accounts Notes And Loans Receivable [Line Items]
Net accounts receivable	7,392	5,246
Business To Business And Other Receivables
Accounts Notes And Loans Receivable [Line Items]
Net accounts receivable	$ 46,493	$ 57,479

Balance Sheet Components - Sc_2

Balance Sheet Components - Schedule of Net Accounts Receivable Balance Concentrations by Major Category (Parenthetical) (Details) - Customer Concentration Risk	3 Months Ended	12 Months Ended
	Mar. 31, 2023 USD ($) Customer	Dec. 31, 2022 USD ($)
Business To Business Receivables
Accounts Notes And Loans Receivable [Line Items]
Number of customers | Customer	2
Gross accounts receivable	$ 7,734,000	$ 9,861,000
Credit insurance policy, deductible amount	$ 400,000	$ 400,000
Credit insurance policy, retention percentage	10%	10%
Business To Business Receivables | Maximum
Accounts Notes And Loans Receivable [Line Items]
Credit insurance policy, coverage limit	$ 12,000,000	$ 12,000,000
Business To Business Receivables One
Accounts Notes And Loans Receivable [Line Items]
Gross accounts receivable	$ 18,757,000	$ 22,641,000

Balance Sheet Components - Sc_3

Balance Sheet Components - Schedule of Allowances for Accounts Receivable (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Receivables [Abstract]
Doubtful accounts	$ 156	$ 77
Sales returns	699	483
Total allowances - accounts receivable	$ 855	$ 560

Balance Sheet Components - Addi

Balance Sheet Components - Additional Information (Details)	3 Months Ended		12 Months Ended
	Mar. 31, 2023 USD ($) Customer	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($) Customer
Schedule Of Balance Sheet Components [Line Items]
Accounts receivable, net	$ 53,885,000		$ 62,725,000
Percentage of Non-US revenue invoiced in Euros	77%	73.20%
Transfer of inventory to rental equipment	$ 1,013,000	$ 533,000
Repairs and maintenance expense	1,311,000	1,030,000
Impairments of long-lived assets	0	$ 0
Goodwill impairment loss	0
Other Noncurrent Assets
Schedule Of Balance Sheet Components [Line Items]
Noncurrent inventories expected to be realized or consumed	1,296,000		1,249,000
Prepaid Expenses and Other Current Assets
Schedule Of Balance Sheet Components [Line Items]
Inventory raw materials	3,041,000		7,017,000
Customer Concentration Risk | Customer One
Schedule Of Balance Sheet Components [Line Items]
Accounts receivable, net	18,757,000		22,641,000
Customer Concentration Risk | Customer Two
Schedule Of Balance Sheet Components [Line Items]
Accounts receivable, net	7,734,000		9,861,000
Customer Concentration Risk | Medicare's Service Reimbursement Programs
Schedule Of Balance Sheet Components [Line Items]
Accounts receivable, net	$ 3,039,000		$ 2,138,000
Sales Revenue, Net | Customer Concentration Risk | Medicare's Service Reimbursement Programs
Schedule Of Balance Sheet Components [Line Items]
Concentration Risk, Percentage	16.60%	12.80%
Net Accounts Receivable | Customer Concentration Risk
Schedule Of Balance Sheet Components [Line Items]
Number of customers | Customer	2		2
Net Accounts Receivable | Customer Concentration Risk | Medicare's Service Reimbursement Programs
Schedule Of Balance Sheet Components [Line Items]
Concentration Risk, Percentage	5.60%		3.40%
Rental Revenue | Customer Concentration Risk | Medicare's Service Reimbursement Programs
Schedule Of Balance Sheet Components [Line Items]
Concentration Risk, Percentage	73.80%	79%
Raw materials | Supplier Concentration Risk | Vendor one
Schedule Of Balance Sheet Components [Line Items]
Concentration Risk, Percentage	34.10%	25.20%
Raw materials | Supplier Concentration Risk | Vendor two
Schedule Of Balance Sheet Components [Line Items]
Concentration Risk, Percentage	13.10%	19.90%
Raw materials | Supplier Concentration Risk | Vendor three
Schedule Of Balance Sheet Components [Line Items]
Concentration Risk, Percentage	7.30%	8.40%

Balance Sheet Components - Brea

Balance Sheet Components - Breakdown of the Company Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Concentration Risk [Line Items]
Revenues	$ 72,162	$ 80,385
U.S. revenue
Concentration Risk [Line Items]
Revenues	53,190	52,444
Non-U.S. revenue
Concentration Risk [Line Items]
Revenues	$ 18,972	$ 27,941

Balance Sheet Components - Sc_4

Balance Sheet Components - Schedule of Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Raw materials and work-in-progress	$ 25,689	$ 26,496
Finished goods	14,291	9,324
Less: reserves	(1,158)	(1,727)
Inventories, net	$ 38,822	$ 34,093

Balance Sheet Components - Su_2

Balance Sheet Components - Summary of Depreciation and Amortization Expense of Rental Equipment and Other Property and Equipment (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Property Plant And Equipment [Line Items]
Depreciation	$ 3,078	$ 2,638
Depreciation and amortization	4,060	3,613
Rental equipment
Property Plant And Equipment [Line Items]
Depreciation	3,078	2,638
Other property and equipment
Property Plant And Equipment [Line Items]
Depreciation and amortization	$ 982	$ 975

Balance Sheet Components - Su_3

Balance Sheet Components - Summary of Property Plant and Equipment and Rental Equipment with Associated Accumulated Depreciation (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Property Plant And Equipment [Line Items]
Property and equipment	$ 97,757	$ 95,113
Accumulated depreciation	51,815	51,844
Property and equipment, net	45,942	43,269
Rental equipment
Property Plant And Equipment [Line Items]
Property and equipment	63,250	61,679
Accumulated depreciation	30,363	31,320
Property and equipment, net	32,887	30,359
Other property and equipment
Property Plant And Equipment [Line Items]
Property and equipment	34,507	33,434
Accumulated depreciation	21,452	20,524
Property and equipment, net	$ 13,055	$ 12,910

Balance Sheet Components - Su_4

Balance Sheet Components - Summary of Property Plant and Equipment and Rental Equipment with Associated Accumulated Depreciation (Parenthetical) (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Rental equipment, allowance	$ 2,765	$ 2,255

Balance Sheet Components - Sc_5

Balance Sheet Components - Schedule of Changes in Carrying Amount of Goodwill (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Balance as of December 31, 2022	$ 32,852
Translation adjustment	35
Balance as of March 31, 2023	$ 32,887

Balance Sheet Components - Sc_6

Balance Sheet Components - Schedule of Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Accounts payable	$ 18,043	$ 18,237
Accrued inventory (in-transit and unvouchered receipts) and trade payables	8,688	10,837
Accrued purchasing card liability	3,459	2,606
Accrued franchise, sales and use taxes	480	492
Other accrued expenses	1,513	1,802
Accounts payable and accrued expenses	$ 32,183	$ 33,974

Balance Sheet Components - Sc_7

Balance Sheet Components - Schedule of Accrued Payroll (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Accrued bonuses	$ 2,076	$ 2,620
Accrued wages and other payroll related items	5,043	4,967
Accrued vacation	3,449	3,133
Accrued employee stock purchase plan deductions	189	470
Accrued payroll	$ 10,757	$ 11,190

Leases - Additional Information

Leases - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Lessee Lease Description [Line Items]
Operating lease, option to extend	options to extend the leases for up to 5 years.
Operating lease, existence of option to extend [true false]	true
Rent expense, including short-term lease cost	$ 972	$ 971
Minimum
Lessee Lease Description [Line Items]
Operating leases, lease term	3 years
Maximum
Lessee Lease Description [Line Items]
Operating leases, lease term	11 years
Operating lease option to extend term	5 years

Leases - Schedule of Right-of-U

Leases - Schedule of Right-of-Use Assets and Operating Lease Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Leases [Abstract]
Cash paid for operating lease liabilities	$ 994	$ 1,008
Operating lease cost	957	$ 975
Non-cash right-of-use assets obtained in exchange for new operating lease obligations	$ 264
Weighted average remaining lease term	2 years 1 month 6 days	2 years 8 months 12 days
Weighted average discount rate	3%	2.90%

Leases - Schedule of Maturities

Leases - Schedule of Maturities of Lease Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Maturities of lease liabilities due in the 12-month period ending March 31,
2024	$ 4,002
2025	3,464
2026	2,787
2027	2,803
2028	2,842
Thereafter	8,675
Operating lease liabilities payments due	24,573
Less imputed interest	(1,824)
Total lease liabilities	22,749
Operating lease liability - current	3,570	$ 3,515
Operating lease liability - noncurrent	19,179	$ 19,764
Total lease liabilities	$ 22,749

Earnings (Loss) per Share - Com

Earnings (Loss) per Share - Computation of Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Numerator—basic and diluted:
Net loss	$ (20,349)	$ (14,214)
Denominator:
Weighted average common shares - basic common stock	23,009,617	22,754,421
Weighted average common shares - diluted common stock	23,009,617	22,754,421
Net loss per share - basic common stock	$ (0.88)	$ (0.62)
Net loss per share - diluted common stock	$ (0.88)	$ (0.62)
Denominator calculation from basic to diluted:
Weighted average common shares - basic common stock	23,009,617	22,754,421
Stock options and other dilutive awards	228,281	88,193
Weighted average common shares - diluted common stock	23,237,898	22,842,614
Shares excluded from diluted weighted average shares:
Shares excluded from diluted weighted-average shares	778,267	958,132
Stock options
Shares excluded from diluted weighted average shares:
Shares excluded from diluted weighted-average shares	286,861	380,890
Restricted stock units and restricted stock awards
Shares excluded from diluted weighted average shares:
Shares excluded from diluted weighted-average shares	491,406	577,242

Income taxes - Additional Infor

Income taxes - Additional Information (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Income Tax Disclosure [Abstract]
Valuation allowance	$ 41,933

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Class Of Stock [Line Items]
Total intrinsic value of options exercised	$ 735	$ 84
Time based restricted stock units
Class Of Stock [Line Items]
Vesting period	4 years
Time based restricted stock awards
Class Of Stock [Line Items]
Vesting period	4 years
Performance and time based restricted stock awards
Class Of Stock [Line Items]
Vesting period	3 years
Performance and time based restricted stock units
Class Of Stock [Line Items]
Vesting period	3 years
Restricted stock units and restricted stock awards
Class Of Stock [Line Items]
Unrecognized compensation cost related to unvested employee excluding estimated forfeitures	$ 28,329
Amount expected to recognized over weighted-average period	2 years 4 months 24 days
Maximum | Stock options
Class Of Stock [Line Items]
Stock option period, expiration	10 years
Vesting period	4 years
Minimum | Stock options
Class Of Stock [Line Items]
Stock option period, expiration	7 years
Vesting period	1 year
2012 Plan
Class Of Stock [Line Items]
Stock option shares outstanding	2,866
Number of equity awards available for grant	0
2014 Plan
Class Of Stock [Line Items]
Stock option shares outstanding	1,931,076
Number of equity awards available for grant	691,309
Terms of shares available for issuance	The number of shares available for issuance under the 2014 Plan also is increased annually on the first day of each fiscal year by an amount equal to the least of:•895,346 shares; •4% of the outstanding shares of common stock as of the last day of the Company’s immediately preceding fiscal year; or•such other amount as the Company’s board of directors may determine.
Common stock capital shares reserved for future issuance maximum annual increase	895,346
Percentage on outstanding shares of common stock	4%
Number of additional number of shares reserve to provision	895,346
2012 Plan | Maximum
Class Of Stock [Line Items]
Stock option shares outstanding	2,328,569
2014 ESPP Plan
Class Of Stock [Line Items]
Number of equity awards available for grant	638,951
Terms of shares available for issuance	The number of shares available for sale under the ESPP is increased annually on the first day of each fiscal year by an amount equal to the least of:•179,069 shares;•1.5% of the outstanding shares of the Company’s common stock on the last day of the Company’s immediately preceding fiscal year; or•such other amount as may be determined by the administrator.
Percentage on outstanding shares of common stock	1.50%
Number of additional number of shares reserve to provision	179,069
Maximum percentage of common stock eligible to purchase through payroll deductions for participants	15%
Maximum number of shares available for participant to purchase during period	1,500
Purchase price as percentage of stock price on offering period	85%
Purchase price as percentage of stock price on exercise date	85%
Potential increase of shares available for issuance	179,069

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Stock Options Activity (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Class Of Stock [Line Items]
Stock Options Outstanding, Beginning balance	348,284
Stock Options, Exercised	(54,432)
Stock Options, Forfeited	(4,125)
Stock Options Outstanding, Ending balance	289,727	348,284
Stock Options, Vested and exercisable	289,727
Stock Options, Vested and expected to vest	289,727
Price per share, Forfeited	$ 44.19
Outstanding, Weighted-average exercise price, Beginning balance	44.21
Weighted-average exercise price, Exercised	7.03
Weighted-average exercise price, Forfeited	44.19
Outstanding, Weighted-average exercise price, Ending balance	51.19	$ 44.21
Weighted-average exercise price, Vested and exercisable	51.19
Weighted-average exercise price, Vested and expected to vest	$ 51.19
Remaining weighted-average contractual term, Outstanding	2 months 19 days	5 months 4 days
Remaining weighted-average contractual term, Vested and exercisable	2 months 19 days
Remaining weighted-average contractual term, Vested and expected to vest	2 months 19 days
Outstanding, Per share average intrinsic value	$ 0.04	$ 2.07
Per share average intrinsic value, Vested and exercisable	0.04
Per share average intrinsic value, Vested and expected to vest	0.04
Minimum
Class Of Stock [Line Items]
Outstanding, Price per share, Beginning balance	1.17
Price per share, Exercised	1.17
Outstanding, Price per share, Ending balance	8.37	1.17
Price per share, Vested and exercisable	8.37
Price per share, Vested and expected to vest	8.37
Maximum
Class Of Stock [Line Items]
Outstanding, Price per share, Beginning balance	83.30
Price per share, Exercised	8.37
Outstanding, Price per share, Ending balance	83.30	$ 83.30
Price per share, Vested and exercisable	83.30
Price per share, Vested and expected to vest	$ 83.30

Stockholders' Equity - Summar_2

Stockholders' Equity - Summary of Restricted Stock Activity (Details)	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Time based restricted stock units
Class Of Stock [Line Items]
Unvested restricted stock units/ awards outstanding, Beginning balance	820,941
Granted	670,317
Vested	(90,677)
Forfeited/canceled	(80,175)
Unvested restricted stock units/ awards outstanding, Ending balance	1,320,406
Performance and time based restricted stock units
Class Of Stock [Line Items]
Unvested restricted stock units/ awards outstanding, Beginning balance	183,197
Granted	536,990
Vested	(15,618)
Forfeited/canceled	(60,904)
Unvested restricted stock units/ awards outstanding, Ending balance	643,665
Restricted stock units
Class Of Stock [Line Items]
Unvested restricted stock units/ awards outstanding, Beginning balance	1,004,138
Granted	1,207,307
Vested	(106,295)
Forfeited/canceled	(141,079)
Unvested restricted stock units/ awards outstanding, Ending balance	1,964,071
Unvested and expected to vest restricted stock units/awards outstanding	1,475,786
Weighted-average grant date fair value per share, Unvested restricted stock units/ awards outstanding, Beginning balance | $ / shares	$ 32.72
Weighted-average grant date fair value per share, Granted | $ / shares	15.84
Weighted-average grant date fair value per share, Vested | $ / shares	38.36
Weighted-average grant date fair value per share, Forfeited/canceled | $ / shares	31.10
Weighted-average grant date fair value per share, Unvested restricted stock units/ awards outstanding, Ending balance | $ / shares	22.82
Weighted-average grant date fair value per share, Unvested and expected to vest restricted stock units/awards outstanding | $ / shares	$ 23.12
Time based restricted stock awards
Class Of Stock [Line Items]
Unvested restricted stock units/ awards outstanding, Beginning balance	786
Vested	(495)
Unvested restricted stock units/ awards outstanding, Ending balance	291
Restricted stock awards
Class Of Stock [Line Items]
Unvested restricted stock units/ awards outstanding, Beginning balance	786
Vested	(495)
Unvested restricted stock units/ awards outstanding, Ending balance	291
Unvested and expected to vest restricted stock units/awards outstanding	272
Weighted-average grant date fair value per share, Unvested restricted stock units/ awards outstanding, Beginning balance | $ / shares	$ 59.55
Weighted-average grant date fair value per share, Vested | $ / shares	69.32
Weighted-average grant date fair value per share, Unvested restricted stock units/ awards outstanding, Ending balance | $ / shares	42.93
Weighted-average grant date fair value per share, Unvested and expected to vest restricted stock units/awards outstanding | $ / shares	$ 42.93

Stockholders' Equity - Summar_3

Stockholders' Equity - Summary of Stock-based Compensation Expense Recognized (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Stock-based compensation expense by type of award:
Stock-based compensation expense	$ 3,442	$ 2,665
Restricted stock units and restricted stock awards
Stock-based compensation expense by type of award:
Stock-based compensation expense	3,305	2,468
Employee Stock Purchase Plan
Stock-based compensation expense by type of award:
Stock-based compensation expense	$ 137	$ 197

Stockholders' Equity - Summar_4

Stockholders' Equity - Summary of Stock-based Compensation Expense Recognized in Income Statement (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 3,442	$ 2,665
Cost of Revenue
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	84	233
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	458	384
Sales and Marketing
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	774	591
General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 2,126	$ 1,457

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Commitments And Contingencies [Line Items]
Outstanding purchase orders due within one year with its outside vendors and suppliers	$ 111,400
Payments received in advance of satisfying performance obligations	869
Revenue recognized	1,674
Lifetime Warranties | Direct-to-Consumer
Commitments And Contingencies [Line Items]
Deferred revenue related to life time warranties	$ 15,729	$ 16,534

Commitments and Contingencies_2

Commitments and Contingencies - Schedule of Changes in Aggregate Product Warranty Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Product warranty liability at beginning of period	$ 19,913	$ 13,726
Accruals for warranties issued	1,681	10,416
Adjustments related to preexisting warranties	1,540	8,234
Settlements made (in cash or in kind)	(3,041)	(12,463)
Product warranty liability at end of period	$ 20,093	$ 19,913

Restructuring Charges - Additio

Restructuring Charges - Additional Information (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Restructuring and Related Activities [Abstract]
Restructuring costs	$ 1,809

Foreign Currency Exchange Con_2

Foreign Currency Exchange Contracts and Hedging - Additional Information (Details)	3 Months Ended
	Mar. 31, 2023 USD ($) Contract	Mar. 31, 2022 USD ($) Contract
Derivatives Fair Value [Line Items]
Unrealized gain (loss) on derivative | $	$ 0	$ (74,000)
Derivative contracts expiration period	1 month
Number of contract ineffective hedges | Contract	0	0
Number of contract designated hedges | Contract	0	8
Number of contract non-designated hedges | Contract	1	1
Non-Designated Derivative Contracts
Derivatives Fair Value [Line Items]
Derivative contracts notional amounts | $	$ 8,041,000	$ 0
Designated Derivative Contracts
Derivatives Fair Value [Line Items]
Derivative contracts notional amounts | $	$ 2,445,000	$ 1,704,000